TickerFacts.

Scilex Holding Co (SCLX): Total Assets

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2021-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$364.98M
As of 2025-12-31
$253.56M
As of 2026-06-30
+61.6%
3-year compound annual growth
2020-12-31: $199.5K2021-12-31: $77.93M2022-12-31: $86.53M2023-12-31: $101.31M2024-12-31: $92.95M2025-12-31: $364.98M$364.98M
2020-12-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$364.98M+292.7%2026-04-10, Balance as of period end
2024-12-31$92.95M-8.2%2026-04-10, Balance as of period end
2023-12-31$101.31M+17.1%2025-03-31, Balance as of period end
2022-12-31$86.53M+11.0%2024-03-12, Balance as of period end
2021-12-31$77.93Mn/c2023-03-07, Balance as of period end
2020-12-31$199.5Kn/a2022-02-24, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
Scilex Holding Co (SCLX)2025-12-31$364.98M+292.7%
Precision Biosciences Inc (DTIL)2025-12-31$154.42M+13.2%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$290.46M+98.3%
C4 Therapeutics, Inc. (CCCC)2025-12-31$359.07M+2.7%
Metagenomi Therapeutics, Inc. (MGX)2025-12-31$221.10M-31.9%
Kymera Therapeutics, Inc. (KYMR)2025-12-31$1.74B+78.2%
Sangamo Therapeutics, Inc (SGMOQ)2025-12-31$59.74M-41.2%
Voyager Therapeutics, Inc. (VYGR)2025-12-31$252.28M-35.8%
Editas Medicine, Inc. (EDIT)2025-12-31$186.53M-45.4%

Compare SCLX, DTIL, XFOR, CCCC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗